Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Dapagliflozin
72%
Glucose
61%
Therapeutic Procedure
50%
Plasma
41%
Gluconeogenesis
38%
Placebo
34%
Insulin
33%
Combination Therapy
32%
Patient
28%
Insulin Resistance
27%
Inpatient
27%
Patient with Type 2 Diabetes
25%
Insulin Sensitivity
25%
Pioglitazone
23%
Glucosuria
21%
Exenatide
19%
Glucose Uptake
18%
Glucagon-Like Peptide-1 Agonist
17%
Chronic Kidney Disease
17%
Cell Function
17%
Hyperglycemia
16%
Cardiovascular System
15%
Glucagon
14%
Obesity
14%
Type 2 Diabetes
14%
Glycemic Control
13%
Clinical Trial
13%
Oral Glucose Tolerance Test
13%
Glucose Tolerance
12%
Finerenone
12%
Heart Function
12%
Insulin Release
11%
Glucagon Like Peptide 1
11%
Mineralocorticoid Antagonist
11%
Kidney
10%
Metabolic Syndrome
10%
Diagnosis
10%
Cotransporter
10%
Antidiabetic Agent
10%
Cells
9%
Diabetes
9%
Adverse Event
8%
Chemotherapeutic Agent
8%
Drug
8%
Cardiovascular Disease
8%
Adipose Tissue
8%
Creatine Phosphate
8%
Empagliflozin
8%
Heart
8%
Nursing and Health Professions
Glucose
15%
Glucose Blood Level
12%
Non Insulin Dependent Diabetes Mellitus
12%
Glucagon Like Peptide 1 Receptor Agonist
11%
World Health Organization
8%
Metabolic Syndrome X
8%
Pioglitazone
8%
Empagliflozin
8%
Dapagliflozin
8%
Diagnosis
8%
Hyperleptinemia
8%
Insulin
8%
Insulin Resistance
7%
Clamp
7%
Acipimox
7%
Diabetes Mellitus
6%
Family
6%
Drug
6%
Hyperglycemia
6%
Glucose Level
6%
Antidiabetic Agent
5%
Obesity
5%
Heart Output
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
33%
Semaglutide
17%
Pioglitazone
17%
Dapagliflozin
15%
Insulin Resistance
12%
Glucose
9%
Obesity
8%
Vascular Disease
8%
Semaglutide
8%
Linagliptin
8%
Empagliflozin
8%
Glitazone Derivative
7%
Diseases
6%
Antidiabetic Agent
5%
Placebo
5%
Drug
5%
Adverse Event
5%
Insulin
5%
